Accès ouvert
2024
article
OpenAlex
Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez et autres
The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the primary safety outcome was the …
us, Ouganda, gb, Afrique du Sud, vn, ht, Zimbabwe, in, br, Malawi, Kenya, pe, th
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Isabella Gomes, Tushar Garg, Gavin Churchyard, Akshay Kumar Gupta et autres
In 2021, the WHO issued a recommendation for initiating TB preventive therapy (TPT) for high-risk contacts of people diagnosed with multidrug-resistant TB (MDR-TB) while acknowledging the paucity of evidence on efficacy.1 However, three ongoing randomized controlled trials evaluating isoniazid, levofloxacin or delamanid …
us, Afrique du Sud, Zimbabwe, pe, in, ht, ph, kr
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Maudy Chido Manyau, Wilfred Gurupira, Dexter Tagwireyi
Background: Oncology pharmacy is a specialty that is central to provision and use of anti-cancer medications. In Zimbabwe, pharmacists rely on a Bachelor of Pharmacy degree (B.Pharm.) and in-house training in the provision of oncology services. This study sought to assess knowledge, …
Zimbabwe
(code pays fourni par la source)